A Phase 1b/2 Study to Evaluate Safety and Clinical Activity of Avelumab in Combination With Bempegaldesleukin(NKTR-214) With or Without Talazoparib or Enzalutamide in Participants With Locally Advanced or Metastatic Solid Tumors

Status: Not yet recruiting

Phase of Trial: Phase I/II

Latest Information Update: 19 Nov 2019

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Avelumab (Primary) ; Bempegaldesleukin (Primary) ; Enzalutamide (Primary) ; Talazoparib (Primary)
Indications Head and neck cancer; Laryngeal cancer; Mouth neoplasm; Oropharyngeal cancer; Prostate cancer; Solid tumours; Squamous cell cancer
Focus Adverse reactions; Therapeutic Use
Sponsors Pfizer

Most Recent Events

14 Nov 2019 Planned End Date changed from 15 May 2023 to 9 Oct 2023.
14 Nov 2019 Planned primary completion date changed from 15 May 2022 to 9 Oct 2022.
14 Nov 2019 Planned initiation date changed from 29 Aug 2019 to 31 Dec 2019.

Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

Login with a username/password associated to an account with a valid subscription
Contact your organization’s admin about adding this content to your AdisInsight subscription
Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Welcome to AdisInsight